AHAM Capital Launches Biotechnology Fund
KUALA LUMPUR – AHAM Asset Management Berhad ("AHAM Capital" or "the Company") announced today the launch of the AHAM World Series – Biotechnology Fund ("the Fund"). The Fund is a wholesale feeder growth fund that provides investors access to the burgeoning opportunities within the biotechnology investment universe.

The Fund will primarily invest in the Janus Henderson Horizon Biotechnology Fund ("Target Fund"), managed by Janus Henderson ("Target Fund Manager"). To achieve its investment objective, the Fund will allocate a minimum of 85% of its net asset value (NAV) to the Target Fund and a maximum of 15% to money market instruments, deposits, and/or cash.

Anton Tan, Chief Officer of Product Solutions & Customer Experience at AHAM Capital said, "Biotechnology companies are at the forefront of scientific innovation, rapidly enhancing our genetic understanding to develop new treatment for major diseases. Over the past decade, we have seen significant improvements in scientific productivity, with the number of drugs receiving FDA approval doubling from 121 to 243 in the past 20 years1.

“Healthcare spending is poised to increase driven by a demographic shift in the US, coupled with aging populations and globalisation. These long-term secular forces create an attractive fundamental backdrop for biotechnology investments. Despite experiencing its worst drawdown on record, the biotech sector is currently trading at a substantial discount to the broader market, presenting a unique 'innovation on sale' opportunity.

“Furthermore, the biotechnology sector offers a broad spectrum of opportunities across small and large-cap companies, providing diversification for investors' portfolios. By positioning themselves in this healthcare revolution, investors can benefit from the continued breakthroughs in biotechnology," Anton adds.

On outlook for the sector Andy Acker, Portfolio Manager of Janus Handerson says, “Biotechnology is currently undergoing unprecedented levels of innovation, thanks to dramatic improvements in life science tools, genetic engineering, and new modalities for treating human diseases such as cancer, autoimmune disease, and rare genetic conditions. These advancements are unearthing opportunities for investors to identify the next blockbuster (billion dollar) therapies and generate alpha for clients.

“At the same time, success in biotech is highly binary in nature, and the disparity between winners and losers are very pronounced. To mitigate this, the biotechnology team at Janus Henderson combine investment experience, scientific expertise, and proprietary statistical models to estimate the probability of success for drugs in clinical development. The team also focuses on the perspectives of physicians, patients, and payers to evaluate the commercial prospects for new therapies to pursue the best investment outcomes for our clients.”

The Fund is suitable for sophisticated investors seeking capital appreciation with a medium to long-term investment horizon. The Base Currency of the Fund is in USD and is available in three currency classes namely, USD Class, MYR Class, and MYR Hedged-Class. The minimum investment amount is $10,000 for the USD Class and $30,000 for the MYR Class and MYR Hedged-Class.

Investors are advised to read and understand the contents of the Fund’s Product Highlights Sheet and Information Memorandum dated 30 May 2024 before investing. To learn more about the Fund, visit aham.com.my.

Lee Sheung Un | [email protected] | +603 2117 6592
Hello, I'm Nadia. How may I help you?
Talk to Nadia
Not sure what to ask? Try these.
  1. I forgot my i-Access password.
  2. How to perform redemption?
  3. What is the minimum amount to open an investment account?
  4. Checklist for deceased redemption.
  5. What is the best fund for me?
<  Slide to cancel
I'm listening ...
Click to stop recording

Managing Director
Teng Chee Wai is the founder of Affin Hwang Asset Management Berhad (Affin Hwang AM). Over the past decade, he has built the Company to be the fastest growing and only independent investment management house in Malaysia’s top three, with an excess of RM47 billion in assets under management as at 31 December 2018.​

​In his capacity as Managing Director / Executive Director, Teng manages the overall business and strategic direction as well as the management of the investment team. His hands-on approach sees him actively involved in investments, product development and marketing. Teng’s critical leadership and regular participation in reviewing and assessing strategies and performance has been pivotal in allowing the Company to successfully navigate the economically turbulent decade.

Teng’s investment management experience spans more than 20 years, and his key area of expertise is in managing absolute return mandates for insurance assets and investment-linked funds in both Singapore and Malaysia. Prior to his current appointments, he was the Assistant General Manager (Investment) of Overseas Assurance Corporation (OAC) and was responsible for the investment function of the Group Overseas Assurance Corporation Ltd.​

​Teng began his career in the financial industry as an Investment Manager with NTUC Income, Singapore. He is a Bachelor of Science graduate from the National University of Singapore and has a Post-Graduate Diploma in Actuarial Studies from City University in London.
Generic Popup